Pyrazole[3,4-d]pyridazine derivatives: Molecular docking and explore of acetylcholinesterase and carbonic anhydrase enzymes inhibitors as anticholinergics potentials

dc.contributor.authorTaslimi, Parham
dc.contributor.authorTurkan, Fikret
dc.contributor.authorCetin, Adnan
dc.contributor.authorBurhan, Hakan
dc.contributor.authorKaraman, Muhammet
dc.contributor.authorBildirici, Ishak
dc.contributor.authorGülçin, İlhami
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T10:11:00Z
dc.date.created2019
dc.date.issued2019
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.description.abstractRecently, the pyridazine nucleus has been widely studied in the field of particular and new medicinal factors as drugs acting on the cardiovascular system. Additionally, a number of thienopyridazines have been claimed to possess interacting biological macromolecules and pharmacological activities such as NAD(P)H oxidase inhibitor, anticancer, and identified as a novel allosteric modulator of the adenosine A1 receptor. The literature survey demonstrates that coumarin, 1,2-pyrazole benzothiazole, and 1,3- thiazole scaffolds are the most versatile class of molecules. In this study, a series of substituted pyrazole[3,4-d]pyridazine derivatives (2a-n) were prepared, and their structures were characterized by Mass analysis, NMR, and FT-IR. These obtained pyrazole [3,4-d]pyridazine compounds were very good inhibitors of the carbonic anhydrase (hCA I and II) isoenzymes and acetylcholinesterase (AChE) with K-i values in the range of 9.03 +/- 3.81-55.42 +/- 14.77 nM for hCA I, 18.04 +/- 4.55-66.24 +/- 19.21 nM for hCA II, and 394.77 +/- 68.13-952.93 +/- 182.72 nM for AChE, respectively. The possible inhibition mechanism of the best-posed pyrazole[3,4-d]pyridazine and pyrazole-3-carboxylic acid derivatives and their interaction with catalytic active pocket residues were determined based on the calculations.
dc.identifier.doi10.1016/j.bioorg.2019.103213
dc.identifier.issn0045-2068
dc.identifier.issn1090-2120
dc.identifier.orcidBurhan, Hakan/0000-0002-2293-7369
dc.identifier.orcidCetin, Adnan/0000-0003-4838-1503
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidSEN, FATIH/0000-0001-9929-9556
dc.identifier.orcidbildirici, ishak/0000-0001-8590-3070
dc.identifier.orcidKaraman, Muhammet/0000-0002-0155-3390;
dc.identifier.pmid31470200
dc.identifier.scopus2-s2.0-85071275433
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.bioorg.2019.103213
dc.identifier.urihttps://hdl.handle.net/11772/22157
dc.identifier.volume92
dc.identifier.wosWOS:000489699400072
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.relation.ispartofBioorganic Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subjectCarbonic Anhydrase
dc.subjectEnzyme Inhibition
dc.subjectComputational Studies
dc.subjectMolecular Docking
dc.titlePyrazole[3,4-d]pyridazine derivatives: Molecular docking and explore of acetylcholinesterase and carbonic anhydrase enzymes inhibitors as anticholinergics potentials
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscoverydadfa319-65b8-4543-92b4-bea49e0139e9

Dosyalar